Lumos Diagnostics Appoints Doug Ward As CEO
21 June 2022
Lumos Diagnostics (ASX:LDX) announced today that its Board of Directors has appointed Doug Ward, a highly experienced diagnostics executive, to serve as CEO.
“We are delighted to welcome Doug Ward as the CEO of Lumos,” said Executive Chair of Lumos Diagnostics and Co-founder of Planet Innovation, Sam Lanyon. “He is a proven leader in the healthcare industry and this role will leverage his vast experience, which spans notable global healthcare companies including Roche, GE, Siemens, Bayer, Chiron and Hologic.”
Mr Ward has held executive positions including CEO during his more than 30-year career. Most recently he served as Vice President, Strategy and Business Development at Hologic where he led a global team responsible for fostering innovation in women’s healthcare to improve clinical results. Prior to joining Hologic, Mr. Ward was the CEO of Personal Genome Diagnostics (PGDx) where he led the organization’s transformation from a clinical laboratory testing service into a fully functional molecular in vitro diagnostics (IVD) company.
“I am thrilled to join the talented team at Lumos Diagnostics,” said Doug Ward, Lumos Diagnostics newly appointed CEO. “The assay development and manufacturing expertise at Lumos is impressive and presents significant growth potential by providing assay R&D for some of the world’s top medical technology companies, as well as developing and commercializing an emerging portfolio of Lumos-branded point-of-care tests.”
Doug joins Lumos Diagnostics at a pivotal time in the Company’s history. Lumos is actively preparing for the commercial launch of its novel point-of-care test, FebriDx®, in the U.S. pending the receipt of a 510(k) clearance from the FDA. In addition, applications for regulatory clearance of Lumos’ ViraDx™ and CoviDx™ point-of-care tests have been filed in key markets such as Canada and Australia.
“We are delighted to welcome Doug Ward as the CEO of Lumos,” said Executive Chair of Lumos Diagnostics and Co-founder of Planet Innovation, Sam Lanyon. “He is a proven leader in the healthcare industry and this role will leverage his vast experience, which spans notable global healthcare companies including Roche, GE, Siemens, Bayer, Chiron and Hologic.”
Mr Ward has held executive positions including CEO during his more than 30-year career. Most recently he served as Vice President, Strategy and Business Development at Hologic where he led a global team responsible for fostering innovation in women’s healthcare to improve clinical results. Prior to joining Hologic, Mr. Ward was the CEO of Personal Genome Diagnostics (PGDx) where he led the organization’s transformation from a clinical laboratory testing service into a fully functional molecular in vitro diagnostics (IVD) company.
“I am thrilled to join the talented team at Lumos Diagnostics,” said Doug Ward, Lumos Diagnostics newly appointed CEO. “The assay development and manufacturing expertise at Lumos is impressive and presents significant growth potential by providing assay R&D for some of the world’s top medical technology companies, as well as developing and commercializing an emerging portfolio of Lumos-branded point-of-care tests.”
Doug joins Lumos Diagnostics at a pivotal time in the Company’s history. Lumos is actively preparing for the commercial launch of its novel point-of-care test, FebriDx®, in the U.S. pending the receipt of a 510(k) clearance from the FDA. In addition, applications for regulatory clearance of Lumos’ ViraDx™ and CoviDx™ point-of-care tests have been filed in key markets such as Canada and Australia.
